FOLH1 and prostate cancer: Molecular imaging of the prostate-specific membrane antigen (PSMA), a glycoprotein expressed 100-1000 times higher in prostate cancer cells, when combined with MpMRI, has shown remarkable accuracy in initial staging and recurrence localization.